Skip to main content
Denosumab and Osteoporosis - A JAMA Review

An overview of denosumab use in osteoporosis (OP)  by Bauer and Ensrud was published in JAMA. 

Lupus Unlocked: Pregnancy and SLE In this webinar, panelists discussed issues such as congenital heart block, lupus ne

Social Author Name
Dr. John Cush
Tweet Content
Lupus Unlocked: Pregnancy and SLE In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential https://t.co/0RfAH7jW0J

Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of P

Social Author Name
Dr. John Cush
Tweet Content
Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of PSO, but higher rate in PSO+PsA (66% vs 39% PSO). 9.4% of PSO+PsA pts on Rx approved for PSO, but not explicitly for PsA. https://t.co/jMqk6gm1RR https://t.co/CQnwYO9yRO

Do SGLT2 and GLP-1 therapies have a role in Lupus? Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-lik

Social Author Name
Dr. John Cush
Tweet Content
Do SGLT2 and GLP-1 therapies have a role in Lupus? Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz

Belimumab in SLE with Mucocutaneous or Vasculitis Findings A post hoc analysis of a belimumab (BEL) inn systemic lupus

Social Author Name
Dr. John Cush
Tweet Content
Belimumab in SLE with Mucocutaneous or Vasculitis Findings A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. https://t.co/BlYWKLJPdb

Valves Gone Wild in SLE Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE)

Social Author Name
Dr. John Cush
Tweet Content
Valves Gone Wild in SLE Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis (LSE), which is characterized by the https://t.co/XcC2POFDRd
Rules on Mycophenolate Use in SLE

Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus. 

2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment

Social Author Name
Dr. John Cush
Tweet Content
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/Q6smp1ZVH2
Subscribe to
×